Selective, irreversible inhibition of mutant EGFR tyrosine kinase (e.g., T790M, exon 19 deletions, L858R) blocks MAPK/PI3K-AKT signaling, leading to apoptosis of EGFR-mutant tumor cells (minimal effect on wild-type EGFR).